MYRIAD GENETICS INC (MYGN)
Health Care · Molecular diagnostics and precision medicine · NASDAQ
Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes.
What MYRIAD GENETICS INC does
Myriad Genetics develops and commercializes molecular diagnostic tests that analyze genes and their expression to assess disease risk, guide treatment decisions, and enable precision medicine across cancer care, prenatal health, and mental health. The company serves healthcare providers and patients with tests for hereditary cancer risk, cancer therapy selection (including HRD testing), molecular residual disease (MRD) detection, and prenatal diagnostics. Myriad operates next-generation laboratory facilities and leverages its commercial reach in community medicine to drive adoption of its comprehensive testing portfolio and digital health solutions.
Themes: ["Cancer Care Continuum diagnostics","Precision medicine / personalized diagnostics","Hereditary cancer testing","Molecular residual disease (MRD) detection","Prenatal health diagnostics","Mental health genomics","Companion diagnostic development","AI-driven oncology diagnostics","Liquid biopsy"]
Fundamentals
- Price$6.10 as of 2026-07-09 close
- Market cap$564M as of 2026-07-10
- 1-year return+6.6% as of 2026-07-09 close
- Net margin-48.2% as of 2026-07-10
- Gross margin+70.0% as of 2026-07-10
- ROE-109.1% as of 2026-07-10
- Debt / equity0.36 as of 2026-07-10
- Revenue growth (YoY)-0.3% as of 2026-07-10
- Revenue CAGR (3y)+6.7% SEC XBRL
- Beta1.62 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.